Takeda’s Entyvio bests AbbVie’s Humira in ulcerative colitis trial
Takeda’s Entyvio has beaten AbbVie’s Humira on achieving clinical remission in patients with ulcerative colitis, in the first trial to directly compare the efficacy and safety of two commonly used biologics for the disease.
Read More
